METTL3 and cancer: METTL3‐mediated m6A modification of microRNAs miR‐100 and miR‐125b are enriched in EVs secreted from the cetuximab‐resistant CRC cells, which upon exposure to non‐resistant cancer cells exhibit resistance to cetuximab.[102]